Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Operating Expenses (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Operating Expenses data on record, last reported at -$98.6 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 382.68% year-over-year to -$98.6 million; the TTM value through Sep 2025 reached -$124.3 million, down 192.69%, while the annual FY2024 figure was -$12.4 million, 110.03% down from the prior year.
  • Operating Expenses reached -$98.6 million in Q3 2025 per STOK's latest filing, down from $41.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $47.3 million in Q1 2025 and bottomed at -$114.1 million in Q4 2024.
  • Average Operating Expenses over 4 years is $14.5 million, with a median of $30.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: plummeted 452.14% in 2024, then skyrocketed 45.23% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $30.4 million in 2022, then grew by 6.39% to $32.4 million in 2023, then tumbled by 452.14% to -$114.1 million in 2024, then increased by 13.51% to -$98.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were -$98.6 million in Q3 2025, $41.1 million in Q2 2025, and $47.3 million in Q1 2025.